Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...
Neuroendocrine tumors (NETs) are difficult to treat due to their high heterogeneity and complexity. SEZ6 (Seizure-related 6 homolog) is a key regulator of dendritic formation and neural signaling and ...
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback